ARK Investment Management LLC Boosts Holdings in Recursion Pharmaceuticals, Inc. $RXRX

ARK Investment Management LLC lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 1.7% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 33,545,499 shares of the company’s stock after acquiring an additional 556,868 shares during the quarter. Recursion Pharmaceuticals accounts for about 1.0% of ARK Investment Management LLC’s holdings, making the stock its 27th biggest holding. ARK Investment Management LLC owned approximately 0.08% of Recursion Pharmaceuticals worth $163,702,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in RXRX. TD Waterhouse Canada Inc. raised its position in Recursion Pharmaceuticals by 64.1% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock worth $29,000 after purchasing an additional 2,200 shares during the period. Xponance Inc. increased its holdings in shares of Recursion Pharmaceuticals by 8.0% in the third quarter. Xponance Inc. now owns 30,020 shares of the company’s stock worth $146,000 after buying an additional 2,221 shares during the period. Main Management ETF Advisors LLC lifted its stake in shares of Recursion Pharmaceuticals by 1.7% in the 2nd quarter. Main Management ETF Advisors LLC now owns 142,914 shares of the company’s stock valued at $723,000 after acquiring an additional 2,328 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in Recursion Pharmaceuticals by 28.1% during the 2nd quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock valued at $56,000 after acquiring an additional 2,428 shares during the period. Finally, Cherry Creek Investment Advisors Inc. boosted its holdings in Recursion Pharmaceuticals by 4.1% during the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 66,781 shares of the company’s stock valued at $326,000 after acquiring an additional 2,649 shares during the period. Institutional investors own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

RXRX has been the subject of several recent research reports. Wall Street Zen upgraded Recursion Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday, February 28th. UBS Group set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. JPMorgan Chase & Co. raised shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $10.00 to $11.00 in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 26th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Stock Up 2.8%

Shares of NASDAQ:RXRX opened at $3.64 on Thursday. Recursion Pharmaceuticals, Inc. has a 12-month low of $2.98 and a 12-month high of $7.18. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of -2.46 and a beta of 0.97. The stock has a fifty day simple moving average of $4.13 and a two-hundred day simple moving average of $4.65. The company has a current ratio of 5.50, a quick ratio of 5.50 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.The firm had revenue of $35.54 million during the quarter, compared to analyst estimates of $24.56 million. During the same quarter in the previous year, the firm earned ($0.53) EPS. Recursion Pharmaceuticals’s quarterly revenue was up 671.7% compared to the same quarter last year. On average, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Najat Khan sold 124,403 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $4.41, for a total value of $548,617.23. Following the transaction, the insider owned 611,135 shares in the company, valued at approximately $2,695,105.35. This represents a 16.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Blake Borgeson sold 220,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $4.20, for a total transaction of $924,000.00. Following the sale, the director directly owned 6,429,863 shares of the company’s stock, valued at $27,005,424.60. This trade represents a 3.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 599,212 shares of company stock valued at $2,562,550. Insiders own 8.43% of the company’s stock.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.